Natera, Inc. $NTRA Shares Bought by Inceptionr LLC

Inceptionr LLC lifted its position in shares of Natera, Inc. (NASDAQ:NTRA) by 55.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,526 shares of the medical research company’s stock after purchasing an additional 2,337 shares during the period. Inceptionr LLC’s holdings in Natera were worth $1,305,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Integrated Wealth Concepts LLC grew its stake in shares of Natera by 6.6% during the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after acquiring an additional 96 shares in the last quarter. NewEdge Advisors LLC lifted its stake in shares of Natera by 68.3% in the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after acquiring an additional 1,847 shares in the last quarter. Focus Partners Wealth boosted its holdings in Natera by 8.6% in the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after purchasing an additional 474 shares during the last quarter. Sivia Capital Partners LLC acquired a new stake in Natera during the 2nd quarter valued at approximately $298,000. Finally, WINTON GROUP Ltd purchased a new stake in Natera during the 2nd quarter worth approximately $558,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Activity

In other Natera news, Director Gail Boxer Marcus sold 11,000 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $217.21, for a total value of $2,389,310.00. Following the completion of the sale, the director directly owned 6,183 shares in the company, valued at $1,343,009.43. This represents a 64.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Steven Leonard Chapman sold 41,124 shares of Natera stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $221.03, for a total value of $9,089,637.72. Following the transaction, the chief executive officer owned 108,743 shares in the company, valued at approximately $24,035,465.29. This trade represents a 27.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 178,872 shares of company stock worth $39,627,696 in the last 90 days. 5.05% of the stock is currently owned by corporate insiders.

Natera Trading Up 0.2%

Shares of NASDAQ:NTRA opened at $264.69 on Friday. The firm’s 50 day moving average is $239.24 and its two-hundred day moving average is $221.33. The firm has a market capitalization of $37.91 billion, a P/E ratio of -162.39 and a beta of 1.51. Natera, Inc. has a 52 week low of $131.81 and a 52 week high of $288.04.

Analyst Ratings Changes

A number of brokerages recently issued reports on NTRA. Robert W. Baird set a $265.00 price target on shares of Natera in a research note on Friday, May 8th. Royal Bank Of Canada started coverage on shares of Natera in a research report on Thursday, June 11th. They issued an “outperform” rating and a $275.00 target price for the company. Wolfe Research initiated coverage on shares of Natera in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 target price on the stock. Wells Fargo & Company lifted their price target on Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a research note on Friday, May 8th. Finally, TD Cowen restated a “buy” rating on shares of Natera in a research note on Wednesday, July 15th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Natera has an average rating of “Moderate Buy” and an average price target of $267.83.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.